# A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer

> **NCT03042702** · PHASE2 · COMPLETED · sponsor: **Innovation Pharmaceuticals, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Kevetrin
- **DRUG:** Kevetrin

## Key facts

- **NCT ID:** NCT03042702
- **Lead sponsor:** Innovation Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-09
- **Primary completion:** 2017-11-10
- **Final completion:** 2017-11-10
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2018-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03042702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03042702, "A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03042702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*